吡格列酮-话题@MedSci

#吡格列酮#

57篇内容 | 2718人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1447988, encodeId=5ac2144e98871, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=CDS 2015：艾塞那肽、胰岛素或吡格列酮对T2DM患者的影响（CONFIDENCE系列研究）, objectType=article, longId=60555, objectId=fdbf6055558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbf6055558, replyNumber=0, likeNumber=60, createdTime=2015-12-14, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbf6055558, moduleTitle=CDS 2015：艾塞那肽、胰岛素或吡格列酮对T2DM患者的影响（CONFIDENCE系列研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdbf6055558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447987, encodeId=e345144e9879e, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=Nature：糖尿病药物吡格列酮或可用于治疗白血病, objectType=article, longId=55955, objectId=ebe255955d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebe255955d2, replyNumber=0, likeNumber=83, createdTime=2015-09-11, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebe255955d2, moduleTitle=Nature：糖尿病药物吡格列酮或可用于治疗白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebe255955d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447986, encodeId=dae4144e98628, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=JAMA：糖尿病患者使用吡格列酮不增加患膀胱癌风险？, objectType=article, longId=53708, objectId=3b0d53e0895, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b0d53e0895, replyNumber=0, likeNumber=84, createdTime=2015-07-25, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b0d53e0895, moduleTitle=JAMA：糖尿病患者使用吡格列酮不增加患膀胱癌风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b0d53e0895)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447985, encodeId=cce1144e985df, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=Lancet：吡格列酮不能改善早期帕金森氏病患者, objectType=article, longId=52471, objectId=0155524e1dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0155524e1dc, replyNumber=0, likeNumber=63, createdTime=2015-06-26, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0155524e1dc, moduleTitle=Lancet：吡格列酮不能改善早期帕金森氏病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0155524e1dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447984, encodeId=aa3a144e9846a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=CIT 2015：吡格列酮对支架内再狭窄的影响, objectType=article, longId=48455, objectId=f6324845581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6324845581, replyNumber=0, likeNumber=70, createdTime=2015-03-22, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6324845581, moduleTitle=CIT 2015：吡格列酮对支架内再狭窄的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6324845581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447983, encodeId=f13f144e98311, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=膀胱癌和服用吡格列酮或罗格列酮之间没有联系, objectType=article, longId=44227, objectId=b35a4422ea3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b35a4422ea3, replyNumber=0, likeNumber=94, createdTime=2014-12-19, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b35a4422ea3, moduleTitle=膀胱癌和服用吡格列酮或罗格列酮之间没有联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b35a4422ea3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447982, encodeId=d859144e982fb, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=J Intern Med：艾塞那肽、胰岛素和吡格列酮对新诊断为2型糖尿病的影响（CONFIDENCE研究）, objectType=article, longId=42372, objectId=cd25423e2c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd25423e2c5, replyNumber=0, likeNumber=68, createdTime=2014-11-12, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd25423e2c5, moduleTitle=J Intern Med：艾塞那肽、胰岛素和吡格列酮对新诊断为2型糖尿病的影响（CONFIDENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd25423e2c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=吡格列酮可降冠心病合并糖尿病DES置入者支架内再狭窄率, objectType=article, longId=40772, objectId=43ae40e72be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43ae40e72be, replyNumber=0, likeNumber=62, createdTime=2014-09-30, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43ae40e72be, moduleTitle=吡格列酮可降冠心病合并糖尿病DES置入者支架内再狭窄率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43ae40e72be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447980, encodeId=f57a144e98071, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=郭艺芳：由艾可拓（吡格列酮）的遭遇所想到的, objectType=article, longId=33287, objectId=2a313328eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a313328eaf, replyNumber=0, likeNumber=58, createdTime=2014-04-14, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a313328eaf, moduleTitle=郭艺芳：由艾可拓（吡格列酮）的遭遇所想到的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a313328eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447979, encodeId=6c9c144e97915, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=中国上市的吡格列酮产品列表, objectType=article, longId=33253, objectId=edf233253ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf233253ef, replyNumber=0, likeNumber=60, createdTime=2014-04-13, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf233253ef, moduleTitle=中国上市的吡格列酮产品列表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf233253ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447978, encodeId=2ac4144e978ed, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=糖尿病药物吡格列酮遭90亿罚单波及国内30余家制药公司, objectType=article, longId=33191, objectId=fdb933191da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdb933191da, replyNumber=0, likeNumber=58, createdTime=2014-04-12, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdb933191da, moduleTitle=糖尿病药物吡格列酮遭90亿罚单波及国内30余家制药公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdb933191da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447977, encodeId=97db144e977c8, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗, objectType=article, longId=20744, objectId=2e7920e44ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e7920e44ae, replyNumber=0, likeNumber=76, createdTime=2013-07-03, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e7920e44ae, moduleTitle=含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e7920e44ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447976, encodeId=0e8d144e97693, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=FDA批准吡格列酮的仿制药上市, objectType=article, longId=9180, objectId=b9419180bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9419180bb, replyNumber=0, likeNumber=100, createdTime=2012-08-23, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9419180bb, moduleTitle=FDA批准吡格列酮的仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9419180bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447975, encodeId=045a144e9754a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=降糖药吡格列酮或面临限制使用, objectType=article, longId=9178, objectId=397791e8b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397791e8b7, replyNumber=0, likeNumber=97, createdTime=2012-08-23, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397791e8b7, moduleTitle=降糖药吡格列酮或面临限制使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397791e8b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447974, encodeId=3ce2144e974d5, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=BMJ：吡格列酮或增膀胱癌风险再次被证实, objectType=article, longId=7058, objectId=9938e0588e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9938e0588e, replyNumber=0, likeNumber=85, createdTime=2012-06-19, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9938e0588e, moduleTitle=BMJ：吡格列酮或增膀胱癌风险再次被证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9938e0588e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447973, encodeId=7379144e973de, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=药监局修订吡格列酮说明书内容, objectType=article, longId=6166, objectId=e914616618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e914616618, replyNumber=0, likeNumber=57, createdTime=2012-05-18, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e914616618, moduleTitle=药监局修订吡格列酮说明书内容, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e914616618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447972, encodeId=a9d5144e9724a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, objectTitle=吡格列酮可能会增加膀胱癌风险, objectType=article, longId=3328, objectId=4369332879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4369332879, replyNumber=0, likeNumber=74, createdTime=2011-11-22, rootId=0, userName=bioon5, userId=28075374720, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4369332879, moduleTitle=吡格列酮可能会增加膀胱癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4369332879)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

吡格列酮

2020-05-29

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

CDS 2015：艾塞那肽、胰岛素或吡格列酮对T2DM患者的影响（CONFIDENCE系列研究）

2015-12-14

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

Nature：糖尿病药物吡格列酮或可用于治疗白血病

2015-09-11

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

JAMA：糖尿病患者使用吡格列酮不增加患膀胱癌风险？

2015-07-25

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

Lancet：吡格列酮不能改善早期帕金森氏病患者

2015-06-26

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

CIT 2015：吡格列酮对支架内再狭窄的影响

2015-03-22

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

膀胱癌和服用吡格列酮或罗格列酮之间没有联系

2014-12-19

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

J Intern Med：艾塞那肽、胰岛素和吡格列酮对新诊断为2型糖尿病的影响（CONFIDENCE研究）

2014-11-12

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

吡格列酮可降冠心病合并糖尿病DES置入者支架内再狭窄率

2014-09-30

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

郭艺芳：由艾可拓（吡格列酮）的遭遇所想到的

2014-04-14

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

中国上市的吡格列酮产品列表

2014-04-13

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

糖尿病药物吡格列酮遭90亿罚单波及国内30余家制药公司

2014-04-12

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗

2013-07-03

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

FDA批准吡格列酮的仿制药上市

2012-08-23

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

降糖药吡格列酮或面临限制使用

2012-08-23

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

BMJ：吡格列酮或增膀胱癌风险再次被证实

2012-06-19

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

药监局修订吡格列酮说明书内容

2012-05-18

bioon5 (审核中...)

前往app查看评论内容

#吡格列酮#

吡格列酮可能会增加膀胱癌风险

2011-11-22

科室
- - 订阅+
  - 更多科室
工具
服务